Roche Remains Positive After Tecentriq Triple-Negative Breast Cancer Data
Clinicians and the company have heralded the IMpassion130 data presented at ESMO which showed that Roche's Tecentriq is the first immunotherapy to improve outcomes in TNBC but a slight blot on the landscape is that pretty much all of the survival benefit was seen in breast cancer patients with PD-L1 positive tumors.
You may also be interested in...
The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.
The PD-L1 inhibitor is the first checkpoint immunotherapy to gain approval in the tough-to-treat disease setting.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.